F0503
5-氟-2′-脱氧尿嘧啶核苷
thymidylate synthase inhibitor
别名:
2′-脱氧-5-氟脲苷, FUDR, 氟脲苷
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C9H11FN2O5
化学文摘社编号:
分子量:
246.19
NACRES:
NA.77
PubChem Substance ID:
EC Number:
200-072-5
Beilstein/REAXYS Number:
90221
MDL number:
UNSPSC Code:
12352208
InChI key
ODKNJVUHOIMIIZ-RRKCRQDMSA-N
InChI
1S/C9H11FN2O5/c10-4-2-12(9(16)11-8(4)15)7-1-5(14)6(3-13)17-7/h2,5-7,13-14H,1,3H2,(H,11,15,16)/t5-,6+,7+/m0/s1
SMILES string
OC[C@H]1O[C@H](C[C@@H]1O)N2C=C(F)C(=O)NC2=O
biological source
synthetic (organic)
assay
≥99% (HPLC)
form
powder
mp
148 °C (lit.)
solubility
water: 50 mg/mL, clear, colorless to faintly yellow
storage temp.
room temp
Quality Level
Gene Information
human ... TYMS(7298)
mouse ... Tyms(22171)
正在寻找类似产品? 访问 产品对比指南
General description
5-氟-2′-脱氧脲核苷，也称为氟脲苷，可在癌细胞中引起DNA介导的细胞毒性作用。氟脲苷可有效治疗肝癌 并且能够清除金黄色葡萄球菌（ Staphylococcus aureus）的毒性。氟脲苷与吉西他滨的二肽前药组合具有更强的细胞渗透性和抗增殖活性。氟脲苷能够有效治疗实体瘤和晚期癌症。
Application
5-氟-2′-脱氧脲核苷已被用作施旺（schwann）细胞增殖、胶质细胞增殖 和背根神经节培养物中非神经细胞的有丝分裂抑制剂。
Biochem/physiol Actions
一种抗肿瘤药物，是胸苷酸合成酶的有效抑制剂 通过低水平支原体感染，可使癌细胞培养物产生FUdR耐受性。
signalword
Danger
hcodes
Hazard Classifications
Acute Tox. 3 Oral
存储类别
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
dust mask type N95 (US), Eyeshields, Faceshields, Gloves
Enhanced absorption and growth inhibition with amino acid monoester prodrugs of floxuridine by targeting hPEPT1 transporters
Tsume Y, et al.
Molecules (Basel), 13(7), 1441-1454 (2008)
Palmitoylation enables MAPK-dependent proteostasis of axon survival factors
Summers DW, et al.
Proceedings of the National Academy of Sciences of the USA, 115(37), E8746-E8754 (2018)
The FDA-approved anti-cancer drugs, streptozotocin and floxuridine, reduce the virulence of Staphylococcus aureus
Yeo WS, et al.
Scientific Reports, 8(1), 2521-2521 (2018)
J A van Laar et al.
European journal of cancer (Oxford, England : 1990), 34(3), 296-306 (1998-06-26)
Despite more than 30 years of intensive studies on new drugs against advanced colorectal cancer, the fluoropyrimidines remain the drugs of choice for systemic treatment and for hepatic artery infusion (HAI). This overview describes new developments in advanced colorectal cancer
The Dipeptide Monoester Prodrugs of Floxuridine and Gemcitabine?Feasibility of Orally Administrable Nucleoside Analogs
Tsume Y, et al.
Pharmaceuticals (Basel, Switzerland), 7(2), 169-191 (2014)
相关内容
Product Information Sheet
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持